AJOVista LLC Purchases Shares of 1,387 Iradimed Corporation (NASDAQ:IRMD)

AJOVista LLC bought a new stake in Iradimed Corporation (NASDAQ:IRMD) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,387 shares of the medical equipment provider’s stock, valued at approximately $66,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Gladius Capital Management LP acquired a new position in Iradimed during the 3rd quarter worth about $36,000. Hsbc Holdings PLC bought a new stake in shares of Iradimed during the third quarter worth approximately $251,000. Summit Global Investments lifted its holdings in Iradimed by 22.5% in the fourth quarter. Summit Global Investments now owns 7,088 shares of the medical equipment provider’s stock valued at $336,000 after buying an additional 1,300 shares during the period. Denali Advisors LLC boosted its stake in Iradimed by 30.5% in the fourth quarter. Denali Advisors LLC now owns 7,700 shares of the medical equipment provider’s stock valued at $366,000 after acquiring an additional 1,800 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Iradimed during the 3rd quarter worth $366,000. 92.34% of the stock is owned by institutional investors and hedge funds.

Iradimed Stock Performance

Shares of IRMD opened at $44.91 on Monday. The firm has a market capitalization of $568.56 million, a PE ratio of 31.70 and a beta of 0.86. The stock has a 50 day simple moving average of $42.62 and a 200 day simple moving average of $43.20. Iradimed Corporation has a 52-week low of $36.12 and a 52-week high of $51.04.

Iradimed (NASDAQ:IRMD) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.01). The firm had revenue of $17.45 million for the quarter. Iradimed had a return on equity of 24.63% and a net margin of 26.48%. Equities research analysts predict that Iradimed Corporation will post 1.39 EPS for the current fiscal year.

Iradimed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Monday, May 20th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date of this dividend is Friday, May 17th. Iradimed’s dividend payout ratio (DPR) is currently 42.55%.

Analyst Ratings Changes

IRMD has been the topic of a number of analyst reports. Singular Research reissued a “buy” rating on shares of Iradimed in a research note on Monday, April 1st. Roth Capital restated a “buy” rating on shares of Iradimed in a research report on Monday, April 22nd. Finally, Roth Mkm reiterated a “buy” rating and issued a $65.00 price target on shares of Iradimed in a research report on Monday, April 22nd.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.